Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy, pharmacokinetics and safety of NewGam IVIG 10% in primary immunodeficiency
2009-011434-10Phase 3Completed
- Sponsor
- Octapharma
- Start
- Oct 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of subcuvia in Immunogenetic disorder and common variable immunodeficiency (CVID), sponsored by Octapharma. Primary endpoint: Serious bacterial infection rate. Started Oct 2009; status: completed.
02
Drugs
subcuvia
03
Conditions
Immunogenetic disordercommon variable immunodeficiency (CVID)
Beyond the preview
Go deeper on 2009-011434-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011434-10.